×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

See Life Break Through Series Continues in New Video About Annmarie

A patient and scientists discuss the next wave of immuno-oncology.


Amgen is proud to reinforce its commitment to serving patients through science, by unveiling the story of Annmarie, a blood cancer patient whose disease relapsed in 2017. Learn about her struggles, her fears and her inspirational journey from relapse to remission.

Also, listen as Amgen scientists describe Amgen’s investigational Bispecific T Cell Engager (BiTE®) platform, the next wave of innovation hoping to advance immuno-oncology.



免费多人疯狂做人爱视频-免费人做人爱的视频